62 results on '"Bayer AG -- Product development"'
Search Results
2. Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024
3. Reports Outline Hemodialysis Study Results from Baylor University College of Medicine (A Phase Ii Randomized Controlled Trial Evaluated Antithrombotic Treatment With Fesomersen In Patients With Kidney Failure On Hemodialysis)
4. ESC Congress 2024: Bayer to Present Phase III KERENDIA® finerenone Data
5. Study Results from University of Tubingen Update Understanding of Life Science (Two-dimensional Sequential Selective Comprehensive Chiralxreversed-phase Liquid Chromatography of Synthetic Phosphorothioate Oligonucleotide Diastereomers)
6. PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study
7. Bayer to Present Investigational Data from Comprehensive KERENDIA® finerenone Clinical Trial Program at Heart Failure 2024 Congress
8. New Liver Cancer Study Results Reported from University of Ulsan (Regorafenib Plus Nivolumab In Unresectable Hepatocellular Carcinoma: the Phase 2 Renobate Trial)
9. New Soft Tissue Sarcomas Research Reported from Royal Marsden Hospital and Institute of Cancer Research [Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group ...]
10. BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease
11. New Clinical Trial Research Findings from University of Washington Discussed [Intrauterine Device-related Uterine Perforation Incidence and Risk (Apex-iud): a Large Multisite Cohort Study]
12. BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson's Disease
13. BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease
14. Research from University of Munich Provides New Study Findings on Breast Cancer (Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast ...)
15. Data on Prostate Cancer Discussed by Researchers at Yokohama City University Medical Center (Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ...) (
16. Recent Studies from Bayer AG Add New Data to Biomarkers (Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes ...)
17. Studies from McMaster University Provide New Data on Ischemia [Factor Xia Inhibition With Asundexian After Acute Non-cardioembolic Ischaemic Stroke (Pacific-stroke): an International, Randomised, Double-blind, Placebo- Controlled, Phase 2b Trial]
18. New Findings from University of Minnesota in the Area of Science Described (The Design and Evaluation of Hybrid Controlled Trials That Leverage External Data and Randomization)
19. Studies in the Area of Biomarkers Reported from Bayer AG (Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes ...)
20. Data on Colon Cancer Detailed by Researchers at Department of Radiology & Oncology (Regorafenib In Patients With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer: Results From a Phase Iib Trial)
21. Investigators at London School of Hygiene and Tropical Medicine Discuss Findings in Cardiology (Statistical Appraisal of 6 Recent Clinical Trials In Cardiology Jacc State-of-the-art Review)
22. Reports from Koc University Highlight Recent Findings in Clinical Trial Research (Sglt-2 Inhibitors In Nephrotic-range Proteinuria: Emerging Clinical Evidence)
23. Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® finerenone and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian
24. Report Summarizes Atrial Fibrillation Study Findings from Stanford University School of Medicine [Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP)]
25. Researchers at Duke Cancer Institute Publish New Study Findings on Monoclonal Antibodies (A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial)
26. A Phase I, Randomized, Placebo-controlled, Open-label, Three Period Crossover Study to Investigate the Effect of Darolutamide and Enzalutamide on Cerebral Blood Flow in Healthy Male Volunteers
27. Reports Summarize Peripheral Artery Disease Study Results from McMaster University (Low-dose Rivaroxaban and Aspirin Among Patients With Peripheral Artery Disease: a Meta-analysis of the Compass and Voyager Trials)
28. How would eliminating race-based adjustments in estimates of kidney function impact clinical trials?
29. Findings in the Area of Clinical Trials and Studies Reported from University of Hull [Eliapixant (Bay 1817080), a P2x3 Receptor Antagonist, In Refractory Chronic Cough: a Randomised, Placebo-controlled, Crossover Phase 2a Study]
30. Reports Summarize Intracranial Hemorrhages Study Results from Duke University (Termination Based On Event Accrual In Per Protocol Versus Intention To Treat In the Rocket Af Trial)
31. Phase III trial of radium Ra 223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
32. Recent Findings by A. Douros and Colleagues in Clinical Trials and Studies Provides New Insights (Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study)
33. Phase II Data Show Bayer's Investigational Compound Copanlisib Achieved Durable Tumor Response in Indolent Non-Hodgkin's Lymphoma
34. Research from University College Yields New Findings on Liver Cancer (mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib)
35. Mount Sinai researchers involved in successful phase 3 trial of drug for liver cancer
36. Study Data from Massachusetts General Hospital Provide New Insights into Cardiology (Gaining Efficiency In Clinical Trials With Cardiac Biomarkers)
37. Researchers from University of Southern Florida Report New Studies and Findings in the Area of Colon Cancer (Comprehensive Literature Review of Randomized Clinical Trials Examining Novel Treatment Advances In Patients With Colon Cancer)
38. Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival
39. Investigators at University of Southern Florida Describe Findings in Colon Cancer (Comprehensive Literature Review of Randomized Clinical Trials Examining Novel Treatment Advances In Patients With Colon Cancer)
40. New Non-Small Cell Lung Cancer Findings Reported from Hospital Center Intercommunal de Creteil [Open-label Phase Ii Trial To Evaluate Safety and Efficacy of Second-line Metronomic Oral Vinorelbine-atezolizumab Combination for Stage-iv ...]
41. Researchers at Bayer AG Describe Findings in Guanylate Cyclase (Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies)
42. Studies in the Area of Hemophilia Reported from Bayer (Safety and Efficacy of Bay 94-9027, an Extended-half-life Factor Viii, During Surgery In Patients With Severe Hemophilia A: Results of the Protect Viii Clinical Trial)
43. Recent Findings from J.T. Hartmann and Co-Authors Provide New Insights into Soft Tissue Sarcomas (Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma)
44. Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
45. Research Conducted by S. Postel-Vinay and Co-Authors Has Provided New Information about Clinical Trials and Studies (First-in-human Phase I Study of the Bromodomain and Extraterminal Motif Inhibitor Bay 1238097: Emerging ...)
46. An Open-label, Non-randomized, Phase I Study to Evaluate the Effect of Copanlisib (a Single Intravenous Dose of 60 mg) on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Metformin (MATE2-K Substrate) in Healthy Volunteers
47. A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A
48. Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
49. An Open Label, Phase I Study of Copanlisib to Evaluate the Pharmacokinetics, Safety and Tolerability in Chinese Patients With Advanced Cancer
50. Bayer announces enrollment of first U.S. patient in Phase III trials of vilaprisan in uterine fibroids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.